New 26-week data from the phase 3 COMP006 study validate the long-term durability, safety, and remission potential of a 2-dose COMP360 psilocybin regimen for highly chronic, treatment-resistant ...
A Prescription Drug User Fee Act target date of November 1, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug ...
High-dose docosahexaenoic acid (DHA) supplementation does not yield a change in brain volume or cognitive performance over 24 months, according to a study publi ...
Those using upadacitinib had lower risk for discontinuing treatment, regardless of previous exposure to treatment ...
Rituximab noninferior to ocrelizumab for suppressing disease activity on T2-weighted MRI between 6 and 24 months.
For most people, the risk for serious muscle disorders from statins is low, according to a study published online June 25 in The Lancet. Ting Cai, DPhil, from t ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results